Taxotere 80mg

It is an antitumor remedy of plant origin (from the taxoid group). It accumulates tubulin in microtubules, prevents their disintegration, which disrupts the process of dividing the tumor cells. Docetaxel is stored for a long time in cells, where its concentration reaches high values. In addition, docetaxel is active against some, though not all, cells that produce in excess P-glycoprotein (P-gP), encoded by the multiple resistance gene to chemotherapeutic remedies.
In vivo docetaxel has a broad spectrum of activity against tumors of mice and transplanted human tumor cells.
The efficacy of docetaxel has been proven in breast cancer, non-small cell lung cancer, ovarian cancer, hormone-resistant prostate cancer, stomach cancer, head and neck cancer.

Indications of Taxotere 80.

Distribution
The pharmacokinetics of docetaxel is dose-dependent and corresponds to a three-phase pharmacokinetic model with T1 / 2 in α, β and γ phases – 4 min, 36 min and 1 h respectively.
Contraindications of Taxotere 80.
– initial number of neutrophils in peripheral blood <1500 / μl; - pronounced violations of the liver function; - Pregnancy; - the period of lactation (breastfeeding); - children and adolescence under 18; - heightened sensitivity ... view full

Dosage of Taxotere 80.

Treatment with Taxotere 80 should be done only under the supervision of a doctor who has experience in carrying out anti-tumor chemotherapy in a specialized hospital.
To prevent hypersensitivity reactions, as well as to reduce fluid retention for all patients (excluding prostate cancer patients) prior to administration of Taxotere, pre-medication with SCS is performed, for example, dexamethasone at a dose of 16 mg / day (8 mg 2 times / day) orally , for 3 days, starting 1 day before the administration of Taxotere.

Overdose of Taxotere.

There are few reports of overdose.
Symptoms: suppression of bone marrow function, peripheral neurotoxicity and mucositis (inflammation of the mucous membranes).

Interaction of the remedy

In vitro studies have shown that the biotransformation of a remedy can change with the simultaneous use of substances inducing or inhibiting cytochrome CYP3A isoenzymes or metabolizing (competitive inhibition) with the participation of cytochrome CYP3A such as cyclosporine, terfenadine, ketoconazole, erythromycin, and trolleandomycin. In this regard, care must be taken with the simultaneous administration of such drugs, given the possibility of pronounced interaction.
With simultaneous use of docetaxel with CYP3A4 isoenzyme inhibitors, such as antifungals from the imidazole group (ketoconazole, itraconazole) and protease inhibitors (ritonavir), caution is necessary.

Side effect of Taxotere 80.

Determination of the frequency of adverse reactions (according to the WHO classification): very often (≥10%), often (≥ 1% and <10%, infrequently (≥ 0.1% and <1%), rarely (≥ 0.01% and <0.1%), very rarely (<0.01%), unknown frequency (when it is not possible to estimate the incidence of adverse reactions according to available data).

Monotherapy with Taxotere (75 mg / m2 and 100 mg / m2)

On the part of the hematopoiesis system: very often – reversible and non-cumulative (not increasing with repeated injections) neutropenia, observed in 96.6% of patients who did not receive G-CSF (the number of neutrophils is reduced to minimum values on average after 7 days, in patients with intensive prior chemotherapy this period may be shorter, the average duration of severe neutropenia is also 7 days), febrile neutropenia, infections; often severe infections due to a decrease in the number of neutrophils in the peripheral blood, severe infections including sepsis and pneumonia (including fatal), thrombocytopenia, bleeding due to thrombocytopenia, anemia, incl. severe anemia; infrequent – severe thrombocytopenia.